New York, NY, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Poppins has announced the launch of its integrated pediatric care platform designed to support working parents with medical, behavioral, and coaching ...
SACRAMENTO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- MedSpa Marketing Partners launches NORA, an AI-powered voice agent, transforming client engagement and appointment bookings for medical spas 24/7.
Paris, France (12 December 2025) – EssilorLuxottica announced today the acquisition of Signifeye, a leading Belgian ophthalmology platform delivering top-tier patient care across 15 eye centers and ...
Tenaya intends to use the net proceeds from the offering to fund the ongoing and planned development of its clinical and early-stage product candidates, particularly TN-201 and TN-401, and for working ...
Mesoblast’s Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved ...
Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) today announced that its wholly-owned subsidiary, Surgery Center Holdings, Inc. (the “Issuer”), priced $425.0 million ...
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...
Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities and BMO Capital Markets acted as joint book-running managers for the offering. LifeSci Capital and Citizens ...
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...
Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program TERN-701 is a highly selective, allosteric BCR-ABL inhibitor ...
U.S. Food and Drug Administration (FDA) approval of the Zenflow Spring ® Implant and Delivery System for the treatment of symptoms associated with benign prostatic hyperplasia (BPH), also known as ...
(“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on December 10, 2025 under BBOT’s 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results